TY - JOUR
T1 - Multiple sclerosis in 2013
T2 - Novel triggers, treatment targets and brain atrophy measures
AU - Montalban, Xavier
AU - Tintoré, Mar
N1 - Funding Information:
The authors thank J.-J. Martin and A. Sieben for the immunohistochemistry images and expert support. The authors receive funding from the Belgian Science Policy Office Interuniversity Attraction Poles programme, the European Centers of Excellence in Neurodegeneration, the Methusalem Excellence programme, the Alzheimer Research Foundation, the Medical Foundation Queen Elisabeth, the Research Foundation Flanders, the Agency for Innovation by Science and Technology Flanders, the University of Antwerp Research Fund, and the MetLife Foundation Award for Medical Research.
PY - 2014/2
Y1 - 2014/2
N2 - 2013 witnessed advances in many aspects of multiple sclerosis (MS) research. Two studies highlighted a potential role for salt as an MS trigger, and one immunomodulatory drug performed well in clinical trials. Moreover, treatment effects of MS drugs were shown to correlate inversely with brain atrophy and disease progression.
AB - 2013 witnessed advances in many aspects of multiple sclerosis (MS) research. Two studies highlighted a potential role for salt as an MS trigger, and one immunomodulatory drug performed well in clinical trials. Moreover, treatment effects of MS drugs were shown to correlate inversely with brain atrophy and disease progression.
UR - http://www.scopus.com/inward/record.url?scp=84893848118&partnerID=8YFLogxK
U2 - 10.1038/nrneurol.2013.274
DO - 10.1038/nrneurol.2013.274
M3 - Review article
C2 - 24394287
AN - SCOPUS:84893848118
SN - 1759-4758
VL - 10
SP - 72
EP - 73
JO - Nature Reviews Neurology
JF - Nature Reviews Neurology
IS - 2
ER -